Incyte Corp INCY

NASDAQ US Health Care Biotechnology

$121.89 ▲ +1.87% (+$2.24)

Index member: S&P 500

Open $120.59

Prev Close $119.65

Day Range $118.26 – $122.07

52W Range $89.25 – $132.60

Market Cap $25.04B

P/E (TTM) 60.70

Beta 0.77

EPS (TTM) $1.88

📋 Company Profile

Industry	Biotechnology
Sector	Health Care
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1993-12-06
Shares Out.	203,830,000
Website	incyte.com/ ↗
Phone	13024986700
Employees	2,844
Revenue	$1.56B
Gross Profit	$1.45B
Net Income	-$784.8M
Free Cash Flow	$684.9M
Total Assets	$7.29B
Total Liabilities	$1.64B
Equity	$5.64B

About Incyte Corp

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Incyte Corp is a publicly traded company under the ticker symbol INCY on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.